Integra LifeSciences Holdings Corporation

to the Integra Life Sciences fourth quarter 2021 financial results call. Today's call is recorded, and I'd now like to turn the conference over to Chris Ward, Senior Director of Investor Relations. Please go ahead, sir.

Thank you, Emma. Good morning, and thank you for joining the Integra Life Sciences fourth quarter and full year 2021 earnings conference call. Joining me on the call this morning are Jan DeWitt, President and Chief Executive Officer, Glenn Coleman, Chief Operating Officer, and Carrie Anderson, Chief Financial Officer. Earlier today, we issued a press release announcing our fourth quarter and full year 2021 financial results. Our corresponding earnings presentation, which will be referenced during the call, is available at integralife.com under Investors and Events and Presentations. Before we begin, I would like to remind you that statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC and in the release. Also in our prepared remarks, we will make reference to both reported and organic revenue growth for 2021. Organic revenue growth excludes the effects of foreign currency acquisitions, including ASL, divestitures, including the sale of our extremities orthopedics business, as well as discontinued products. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. And lastly, our comments today will include certain non-GAAP financial measures. Reconciliation of any non-GAAP financial measures can be found in today's press release, which is an exhibit to Integra's current report, Form 8-K, filed today with the SEC. And with that, I will now turn the call over to Jan.

Thank you, Chris, and good morning, everyone. Thank you for joining us. I would like to make a few brief remarks at the start of this call, my first earnings call with Integra. Let me start with congratulating and thanking our employees. Since I joined the company, our team's dedication and resilience across the globe have been readily apparent to me. I look forward to working alongside this team in the months and years ahead as we chart our exciting path forward. Through our first few months on board, I'm quite impressed with and proud of what Integra has achieved in recent years. I'm thrilled to be leading this organization with its strong legacy, values, and capabilities into the future. Integra has a sound business platform with significant untapped future potential. And it will be my focus to lead our team into reaching its full potential. 2021 was a successful year for the company despite many ongoing challenges from the global pandemic. We've run a steady ship through the rough COVID seas, but while doing so, we've also driven significant changes in the portfolio and strengthened our platform for the future. And throughout this unusual year, our team showed tremendous resilience in serving our customers and patients while continuing to move our growth priorities forward. During today's presentation, Glenn will go into more detail about the 2021 performance and our key accomplishments. And then Kerry will provide a deeper look at our financial performance and will share our outlook for 22. Finally, I will conclude with my thoughts on our key initiatives for accelerating growth and the company's areas for focus for this year. So with that, let me turn it over to Glenn.